

### MOLECULAR BIOMARKER RESULTS IN ONLY 3 HOURS! THINK IDYLLA™

The Idylla™ solution is a revolutionary, fully automated, real-time PCR-based molecular testing system designed to offer results in only 3 hours. Accessible on demand and without the need for batching. It makes molecular testing easy, fast and suitable for any lab.





Highly sensitive, fully automated biomarker testing



Results in only 3 hours



On solid and liquid biopsies



Limited amount of sample needed



24/7 testing on single samples - no need for batching and losing time



In-house testing suitable for any lab setting – no need to send samples out



Complementary to NGS





# GENE EXPRESSION SIGNATURES AND BIOMARKER TESTS AS GUIDANCE FOR CLINICAL DECISION MAKING.

#### IN VITRO DIAGNOSTICS (IVD)



#### MELANOMA - Merlin™ Assay

Merlin helps identify melanoma patients who may forgo the sentinel lymph node biopsy. The Merlin™ Assay is being commercialized in Europe by Biocartis as a CE-IVD marked manual kit, ahead of the launch of an Idylla™ version of the test which is under development.





#### LIVER CANCER - HepatoPredict

Prognostic tool supporting the decision of liver transplantation in hepatocellular carcinoma.






#### COLORECTAL CANCER - ColoNode®

Novel IVD for the detection of tumor cells in lymph nodes of colorectal cancer patients.



## RESEARCH ASSAYS (FOR RESEARCH USE ONLY - NOT FOR USE IN DIAGNOSTIC PROCEDURES)



#### THYROID CANCER - Idylla™ ThyroidPrint® Assay

First-in-class cartridge-based assay for risk stratification of indeterminate thyroid nodules.





## BREAST CANCER APIS PIK3CA qPCR Kit

For efficient and reliable PIK3CA gene mutations detection via quantitative PCR (qPCR).



#### **APIS ESR1 dPCR Kit**

For reliable and precise ESR1 mutations detection via digital PCR (dPCR).

#### **APIS ESR1 Mutations Kit**

For easy and fast ESR1 mutations detection via quantitative PCR (qPCR).

#### **APIS ESR1 Mutations Controls**

For quality control of assays detecting ESR1 mutations.

#### **APIS Breast Cancer Subtyping Kit**

For fast classification of breast cancer via RT-qPCR.



#### OFFERING A BROAD ONCOLOGY PROGRAM AND TEST MENU



Biocartis NV Generaal De Wittelaan 11B 2800 Mechelen - Belgium +32 15 632 888

Follow us on **f X in** www.biocartis.com customerservice@biocartis.com



Idylla™ Platform is CE-marked in Europe in compliance with EU IVD Regulation 2017/746, listed as a class II device in the US under establishment registration 3009972873, and registered in many other countries. Merlin™ Assay is CE-marked in Europe in compliance with the EU IVD directive 98/79/EC, developed by SkylineDx and distributed by Biocartis, and available for sale in Europe. HepatoPredict is CE-marked in Europe in compliance with the EU IVD directive 98/79/EC, developed by Ophiomics and distributed by Biocartis, and available for sale in Europe. ColoNode® is a is CE-marked in Europe in compliance with the EU IVD directive 98/79/EC, developed by Hiloprobe and distributed by Biocartis, and available for sale in selected European countries. Idylla™ ThyroidPrint is for Research Use Only (RUO), not for use in diagnostic procedures, developed by GeneproDX and distributed by Biocartis. APIS ESR1 Mutations Kit, APIS ESR1 Mutations Controls and APIS Breast Cancer Subtyping Kit are for Research Use Only (RUO), not for use in diagnostic procedures, developed by APIS and distributed by Biocartis, available for sale in selected European countries.

Biocartis and Idylla $^{\text{IM}}$  are registered trademarks in Europe, the US and many other countries. The Biocartis and Idylla $^{\text{IM}}$  trademarks and logos are used trademarks owned by Biocartis. Idylla $^{\text{IM}}$  is available for sale in Europe, the US and many other countries. Please check availability with a Biocartis representative. © October 2024, Biocartis NV. All rights reserved.